肥厚型心肌病一级预防ICD使用与结局的全球差异
该研究基于国际Sarcomeric Human Cardiomyopathy Registry,比较美国与非美国三级肥厚型心肌病中心的一级预防ICD植入率及结局。美国中心植入率是非美国中心的2.27倍,ICD受者恰当治疗率更低,未植入ICD者心脏性猝死/复苏后心脏骤停发生率无显著差异。
要点
- 美国中心HCM患者一级预防ICD植入率显著高于非美国中心(HR 2.27)。
- 美国ICD受者恰当ICD治疗率显著低于非美国中心(HR 0.52)。
- 未植入ICD者心脏性猝死/复苏后心脏骤停发生率两地无显著差异。
核心结论
- 美国中心HCM患者一级预防ICD植入率高于非美国中心,且美国ICD受者恰当治疗率更低,提示植入人群风险较低。
- 未植入ICD的美国与非美国患者心脏性猝死/复苏后心脏骤停发生率无显著差异。
研究设计与样本
- 国际多中心注册研究(Sarcomeric Human Cardiomyopathy Registry),纳入8个美国中心2650例和5个非美国中心2660例HCM患者。
- 采用多变量Cox比例风险模型比较美国与非美国中心之间的结局。
主要发现
- 美国中心一级预防ICD植入率是非美国中心的2.27倍(HR 2.27 [1.89-2.74])。
- 在基于HCM risk-SCD评分5年SCD风险≥6%的高危个体中,美国中心植入率仍更高(HR 3.27 [1.76-6.05])。
- 美国ICD受者传统SCD危险因素较少。
- ICD受者中,美国中心恰当ICD治疗率显著低于非美国中心(HR 0.52 [0.28-0.97])。
- 未植入ICD者中,美国与非美国中心心脏性猝死/复苏后心脏骤停发生率无显著差异(HR 1.21 [0.74-1.97])。
临床怎么用
- 两地一级预防ICD植入率存在显著差异,提示需优化ICD分配策略。
- 美国ICD受者恰当治疗率较低,临床应关注植入人群的风险匹配。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Risk stratification algorithms for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) and regional differences in clinical practice have evolved over time. We sought to compare primary prevention implantable cardioverter defibrillator (ICD) implantation rates and associated clinical outcomes in US vs. non-US tertiary HCM centres within the international Sarcomeric Human Cardiomyopathy Registry. METHODS AND RESULTS: We included patients with HCM enrolled from eight US sites (n = 2650) and five non-US (n = 2660) sites and used multivariable Cox-proportional hazards models to compare outcomes between sites. Primary prevention ICD implantation rates in US sites were two-fold higher than non-US sites (hazard ratio (HR) 2.27 [1.89-2.74]), including in individuals deemed at high 5-year SCD risk (≥6%) based on the HCM risk-SCD score (HR 3.27 [1.76-6.05]). US ICD recipients also had fewer traditional SCD risk factors. Among ICD recipients, rates of appropriate ICD therapy were significantly lower in US vs. non-US sites (HR 0.52 [0.28-0.97]). No significant difference was identified in the incidence of SCD/resuscitated cardiac arrest among non-recipients of ICDs in US vs. non-US sites (HR 1.21 [0.74-1.97]). CONCLUSION: Primary prevention ICDs are implanted more frequently in patients with HCM in US vs. non-US sites across the spectrum of SCD risk. There was a lower rate of appropriate ICD therapy in US sites, consistent with a lower-risk population, and no significant difference in SCD in US vs. non-US patients who did not receive an ICD. Further studies are needed to understand what drives malignant arrhythmias, optimize ICD allocation, and examine the impact of different ICD utilization strategies on long-term outcomes in HCM.
引用
- Nauffal V, Marstrand P, Han L, et al. Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. Eur Heart J. 2021. PMID: 34491319. doi:10.1093/eurheartj/ehab598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。